Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort (TTT)

Assiut University

Status: Not yet enrolling

Conditions: Aplastic Anaemia (AA)

Study type: Observational

Funder types: Other

Identifiers

NCT07131878

Aquired Aplastic Anemia ttt

Details and patient eligibility

About

The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children

Full description

This study will be conducted to investigate the clinical outcomes, and treatment modalities of patients diagnosed with aquired aplastic anaemia at Assiut University children Hospital

The main question it aims to answer is:

Enrollment: 35 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity <25% and at least two of the following: absolute neutrophil count <500/μL, platelet count <20,000/μL, absolute reticulocyte count <60,000/μL)123.
• The bone marrow biopsy should be compitable with diagnosis
• Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
• Patients with complete medical records, including diagnostic, laboratory, and treatment data

Exclusion criteria

• Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
• Patients with incomplete or missing essential data in their medical records.
• Patients diagnosed outside the specified study period or managed primarily at other institutions.
• Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
• Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded

Trial design

35 participants in 2 patient groups

patient diagnosed with aplastic anemia from July 2023 to sept 2025

patient diagnosed with aplastic anemia from Sept 2025 to July 2026